A new post-hoc analysis of the SELECT randomized trial examined whether baseline frailty changed the pattern of results assigned to Semaglutide or placebo. The authors of this Semaglutide analysis report no detectable heterogeneity in the primary cardiovascular composite across their three frailty categories. In other words, the analysis did not find statistical evidence that baseline frailty modified the relative result observed in the trial.
This is an analysis within an existing randomized trial, not a new trial designed around frailty. It is useful because frailty is common in older populations with cardiovascular disease, yet the balance of trial outcomes can be difficult to interpret when baseline vulnerability differs between participants. It does not establish an individual prediction, a prescribing decision, or an instruction for use.
What the authors analyzed
SELECT enrolled adults with established cardiovascular disease, overweight or obesity, and no diabetes. For this analysis, investigators constructed a 31-item frailty index using the cumulative-deficit approach, then grouped 17,604 participants as not frail, more frail, or most frail at baseline. The published paper reports that 31% were in the lowest category, 47% in the middle category, and 22% in the highest category.
The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Semaglutide was compared with placebo under the parent trial’s randomized framework. The frailty analysis asked a narrower question than the original trial: whether the relative pattern for that composite differed by baseline frailty category.
The reported result across the three groups
Event incidence rose as baseline frailty increased. The reported hazard ratios for Semaglutide versus placebo were 0.84 in the lowest frailty category, 0.70 in the middle category, and 0.92 in the highest category. Their confidence intervals differed in width, but the authors report a P value of .09 for interaction, which did not meet their threshold for detectable effect modification.
The paper also reports no detectable frailty interaction for a composite heart-failure outcome, all-cause hospitalization, or all-cause mortality. Health-related quality-of-life scores appeared to show a larger relative change in participants with higher baseline frailty, but this was a secondary finding within the post-hoc analysis. Semaglutide-related discontinuations due to adverse events also varied by baseline frailty in the reported interaction analysis.
These results should be read as a pattern within SELECT, rather than as three separate confirmatory trials. The point estimates do not prove equal effects in every frailty group. They show that the study did not detect a statistically reliable difference between the groups.
Why the post-hoc label matters
Randomization in the parent study protects the assigned comparison, but subgroup analyses introduce additional uncertainty. A frailty index is also a constructed measure, built from multiple health deficits rather than a single laboratory value. Different index items, cutoffs, populations, or outcome definitions could produce a different subgroup pattern.
The analysis is nevertheless more informative than assuming that all trial participants have the same baseline reserve. Semaglutide appeared in all three categories, and Semaglutide remained the assigned intervention across those analytical strata. The formal interaction tests provide the correct frame for comparing the categories. Looking only at one hazard ratio from each group could overstate apparent differences that arose through sampling variation.
What this paper does not compare
The study does not compare Semaglutide with Tirzepatide or Retatrutide. They are distinct compounds and neither is an interchangeable extension of this analysis. For separate compound context, see the Retatrutide research reference hub.
It also does not show that a frailty score alone can determine a person’s expected outcome. SELECT excluded people with diabetes, used a specific cardiovascular-risk population, and evaluated outcomes within a controlled trial. Semaglutide results from that setting should not be generalized beyond its population without further evidence.
Peptra Labs materials sit within a Research Use Only boundary. The site’s research peptide risk profile likewise distinguishes research context from claims about human use. Neither resource is evidence that a Peptra Labs material was involved in SELECT.
The proportionate takeaway is that this secondary SELECT analysis found no detectable modification of the primary cardiovascular result by its baseline frailty categories. It adds a structured subgroup view to the parent trial, while leaving important questions about other populations, other frailty measures, and individual-level interpretation open.
References
- Ostrominski JW, Plutzky J, Scirica BM, et al. Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial. JAMA Cardiology. 2026. PubMed
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023. Article
- Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatrics. 2008. Article
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
